Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Recent clinical studies have shown promising results for Dexamethasone + Elotuzumab + Lenalidomide. These studies confirm earlier hopes of improving treatment outcomes.
Elotuzumab, an mAb targeted SLAM7 in the plasma cells and natural killer cells surface, is the first mAb approved for the treatment of relapsed-refractory Multiple Myeloma (MM) / Plasmocytoma in combination with lenalidomide and dexamethasone.
This approval was the final result of several preclinical and Phase …